Cartesian Therapeutics, Inc.
RNAC
Rang în acțiuni
#18507
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Preț acțiune
$6.11
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$184.86M
Schimbare (1 zi)
-2.55%
Schimbare (1 an)
815.63%
Țară
US
Tranzacționează Cartesian Therapeutics, Inc. (RNAC)
Categorie
Healthcare
Raport P/B pentru Cartesian Therapeutics, Inc. (RNAC)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Cartesian Therapeutics, Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Cartesian Therapeutics, Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
